Research behind a blockbuster anti-stroke drug could have included fake data while its serious and potentially fatal side effects were kept secret, official US documents have revealed

Research behind a blockbuster anti-stroke drug could have included fake data while its serious and potentially fatal side effects were kept secret, official US documents have revealed.In 2009, distinguished British medical journal The Lancet published a major study on the blood thinner rivaroxaban, which appeared to show it was safe and effective.But now the journal has warned of 'inaccuracies' in the trial data and said that it would be investigating the research further.Rivaroxaban, often sold under the brand name Xarelto, is approved by health watchdogs NICE for the prevention of stroke and embolisms - blocked blood vessels, usually caused by…